Trials / Completed
CompletedNCT01253564
A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
An Open-label, Pilot Study of RO5185426 in Previously Treated Metastatic Melanoma Patients With Brain Metastases
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label study will assess the safety and efficacy of RO5185426 in previously treated metastatic melanoma patients with brain metastases. Patients will receive RO5185426 at a dose of 960 mg twice daily orally until disease progression or unacceptable toxicity occurs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO5185426 | 960 mg b.i.d. orally |
Timeline
- Start date
- 2010-11-22
- Primary completion
- 2012-03-14
- Completion
- 2012-03-14
- First posted
- 2010-12-03
- Last updated
- 2017-07-31
- Results posted
- 2015-08-07
Locations
2 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT01253564. Inclusion in this directory is not an endorsement.